» Articles » PMID: 35582564

Mitochondrial Determinants of Chemoresistance

Overview
Date 2022 May 18
PMID 35582564
Authors
Affiliations
Soon will be listed here.
Abstract

Chemoresistance constitute nowadays the major contributor to therapy failure in most cancers. There are main factors that mitigate cell response to therapy, such as target organ, inherent sensitivity to the administered compound, its metabolism, drug efflux and influx or alterations on specific cellular targets, among others. We now know that intrinsic properties of cancer cells, including metabolic features, substantially contribute to chemoresistance. In fact, during the last years, numerous reports indicate that cancer cells resistant to chemotherapy demonstrate significant alterations in mitochondrial metabolism, membrane polarization and mass. Metabolic activity and expression of several mitochondrial proteins are modulated under treatment to cope with stress, making these organelles central players in the development of resistance to therapies. Here, we review the role of mitochondria in chemoresistant cells in terms of metabolic rewiring and function of key mitochondria-related proteins.

Citing Articles

Mitochondrial Dysfunction: Effects and Therapeutic Implications in Cerebral Gliomas.

Caruso G, Laera R, Ferrarotto R, Garcia Moreira C, Kumar R, Ius T Medicina (Kaunas). 2024; 60(11).

PMID: 39597073 PMC: 11596904. DOI: 10.3390/medicina60111888.


Superior Anticancer and Antifungal Activities of New Sulfanyl-Substituted Niclosamide Derivatives.

Ma J, Veeragoni D, Ghosh H, Mutter N, Barbosa G, Webster L Biomedicines. 2024; 12(7).

PMID: 39062194 PMC: 11275179. DOI: 10.3390/biomedicines12071621.


Mitochondrial-Stem Cell Connection: Providing Additional Explanations for Understanding Cancer.

Martinez P, Baghli I, Gourjon G, Seyfried T Metabolites. 2024; 14(4).

PMID: 38668357 PMC: 11051897. DOI: 10.3390/metabo14040229.


Mitochondrion: Main organelle in orchestrating cancer escape from chemotherapy.

Mostafavi S, Eskandari N Cancer Rep (Hoboken). 2023; 7(2):e1942.

PMID: 38151790 PMC: 10849933. DOI: 10.1002/cnr2.1942.


Mitochondria in Cancer Stem Cells: From an Innocent Bystander to a Central Player in Therapy Resistance.

Garimella S, Gampa S, Chaturvedi P Stem Cells Cloning. 2023; 16:19-41.

PMID: 37641714 PMC: 10460581. DOI: 10.2147/SCCAA.S417842.


References
1.
Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

2.
Mailloux R, Adjeitey C, Harper M . Genipin-induced inhibition of uncoupling protein-2 sensitizes drug-resistant cancer cells to cytotoxic agents. PLoS One. 2010; 5(10):e13289. PMC: 2953501. DOI: 10.1371/journal.pone.0013289. View

3.
Derdak Z, Mark N, Beldi G, Robson S, Wands J, Baffy G . The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res. 2008; 68(8):2813-9. PMC: 2386271. DOI: 10.1158/0008-5472.CAN-08-0053. View

4.
Flavin R, Peluso S, Nguyen P, Loda M . Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010; 6(4):551-62. PMC: 3197858. DOI: 10.2217/fon.10.11. View

5.
Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View